Jasper Therapeutics (NASDAQ:JSPRW – Get Free Report) will likely be releasing its results before the market opens on Thursday, November 5th. Analysts expect Jasper Therapeutics to post earnings of ($0.08) per share and revenue of $12.00 million for the quarter.
Jasper Therapeutics Price Performance
JSPRW stock opened at $0.00 on Tuesday. Jasper Therapeutics has a 12 month low of $0.00 and a 12 month high of $0.15.
About Jasper Therapeutics
Jasper Therapeutics, Inc is a clinical-stage biotechnology company focused on developing therapies for diseases involving hematopoietic stem cells, bone marrow transplantation and immune system disorders. The company’s research has centered on antibody-based medicines designed to enable or improve stem cell transplantation and gene therapy procedures.
Jasper’s leading investigational product is briquilimab, formerly known as JSP191. Briquilimab is a monoclonal antibody that targets CD117, a receptor involved in the survival and maintenance of hematopoietic stem cells.
Featured Stories
- Five stocks we like better than Jasper Therapeutics
- SpaceX Sent Verizon and T-Mobile Stocks Tumbling—Did Wall Street Overreact?
- SpaceX Starlink’s Telecom Ground Game Takes Shape
- AST SpaceMobile’s Brazil Breakthrough Could Set the Stage for a Q3 Stock Rebound
- AbbVie’s Humira Era Is Fading, But Its New Growth Engines Face Another Test
Receive News & Ratings for Jasper Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jasper Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.png){kind=logo}
